Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...
Affymetrix Inc. has announced the publication of the MicroArray Quality Control (MAQC) study, a collaborative effort led by the FDA that included 137 scientists from private and public sector ...
Affymetrix DNA analysis technology enables scientists to look at as many as 500,000 SNPs throughout the entire human genome, according to the company. Each SNP on a GeneChip Human Mapping Array is ...
Mindy Lee-Olsen, 408-731-5523 (Media)Vice President, Marketing ServicesorDoug Farrell, 408-731-5285 (Investors)Vice President, Investor Relations (NASDAQ:AFFX) announced today the availability of ...
The DNA marketplace is changing: the technology is maturing, whole human genome arrays, as well as those of model organisms, are beginning to make it onto the market, and researchers have more choices ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ:AFFX) today announced commercialization of the next-generation human transcriptome array demonstrated by Stanford University researchers ...
Genomatix Software GmbH has announced that it has achieved GeneChip-compatible™ status for several products with the Affymetrix Inc. GeneChip ® microarray platform and that it has joined Affymetrix ...
Unique and optimized solution provides highly sensitive and reproducible RNA amplification and labeling from archived FFPE samples for biomarker discovery and validation on industry-leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results